Licensee Quark Announces Positive AKI Results

Licensee Quark Pharmaceuticals announces positive Phase 2 data in Acute Kidney Injury

27 July 2017

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, notes Quark Pharmaceutical, Inc's ("Quark") press release "Quark Pharmaceuticals Reports Positive Results from a Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury (AKI) in Subjects at High Risk of AKI Following Cardiac Surgery". Quark reported that the trial's primary endpoint and multiple secondary endpoints were met.

Quark holds a licence to Silence's chemical modification technology. Silence is eligible to receive either approximately 2% royalties from Quark (on QPI-1002) plus milestones, or 15% of the clinical, regulatory and commercial milestone payments and royalties received by Quark from its partner Novartis.

Quark's full announcement can be found here: http://quarkpharma.com/?p=12442.

Enquiries:

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.